- Home
- HCM vs NNNN Comparison
HCM vs NNNN Comparison
Compare HCM & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- NNNN
- Stock Information
- Founded
- HCM 2000
- NNNN 2021
- Country
- HCM Hong Kong
- NNNN Germany
- Employees
- HCM N/A
- NNNN N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HCM Health Care
- NNNN Health Care
- Exchange
- HCM Nasdaq
- NNNN Nasdaq
- Market Cap
- HCM 2.6B
- NNNN 2.2B
- IPO Year
- HCM N/A
- NNNN 2025
- Fundamental
- Price
- HCM $16.01
- NNNN $28.84
- Analyst Decision
- HCM Sell
- NNNN
- Analyst Count
- HCM 1
- NNNN 0
- Target Price
- HCM $13.75
- NNNN N/A
- AVG Volume (30 Days)
- HCM 56.9K
- NNNN 73.9K
- Earning Date
- HCM 08-07-2025
- NNNN 10-23-2025
- Dividend Yield
- HCM N/A
- NNNN N/A
- EPS Growth
- HCM N/A
- NNNN N/A
- EPS
- HCM 0.53
- NNNN 0.06
- Revenue
- HCM $602,197,000.00
- NNNN $8,185,146.00
- Revenue This Year
- HCM N/A
- NNNN N/A
- Revenue Next Year
- HCM $15.49
- NNNN N/A
- P/E Ratio
- HCM $5.91
- NNNN $545.12
- Revenue Growth
- HCM N/A
- NNNN 21.95
- 52 Week Low
- HCM $11.51
- NNNN $5.18
- 52 Week High
- HCM $21.50
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- HCM 48.16
- NNNN 35.78
- Support Level
- HCM $17.19
- NNNN $22.08
- Resistance Level
- HCM $16.35
- NNNN $51.33
- Average True Range (ATR)
- HCM 0.29
- NNNN 5.72
- MACD
- HCM -0.01
- NNNN -0.91
- Stochastic Oscillator
- HCM 21.74
- NNNN 21.32
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.